Figure 4
Incidence rates (A) (events per 100 patient years), treatment effect of empagliflozin compared with placebo (B), and estimated cumulative incidence function (C) for hypertensive urgencies according to different criteria. Treatment effect based on Cox regression model adjusted for age, baseline estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula), baseline left ventricular ejection fraction as linear covariates and region, baseline diabetes status, and sex. Patients with increased blood pressure values at baseline were not at risk for occurrence of the respective endpoint. AE, adverse event; CI, confidence interval; DBP; diastolic blood pressure; HR, hazard ratio; SBP, systolic blood pressure

Incidence rates (A) (events per 100 patient years), treatment effect of empagliflozin compared with placebo (B), and estimated cumulative incidence function (C) for hypertensive urgencies according to different criteria. Treatment effect based on Cox regression model adjusted for age, baseline estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula), baseline left ventricular ejection fraction as linear covariates and region, baseline diabetes status, and sex. Patients with increased blood pressure values at baseline were not at risk for occurrence of the respective endpoint. AE, adverse event; CI, confidence interval; DBP; diastolic blood pressure; HR, hazard ratio; SBP, systolic blood pressure

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close